BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25921449)

  • 1. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.
    Toledano A; Luporsi E; Morere JF; Scotté F; Laribi K; Barrière J; Huot-Marchand P; Duvillié L; Concas VH; Bugat R
    Support Care Cancer; 2016 Jan; 24(1):67-75. PubMed ID: 25921449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
    Steinmetz T; Tschechne B; Harlin O; Klement B; Franzem M; Wamhoff J; Tesch H; Rohrberg R; Marschner N
    Ann Oncol; 2013 Feb; 24(2):475-482. PubMed ID: 23071262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).
    Luporsi E; Toledano A; Spaeth D; Scotté F; Espié M; Perot S; Duvillié L; Pithois Merli I; Bugat R
    Support Care Cancer; 2017 Mar; 25(3):973-982. PubMed ID: 27915456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A; Mircescu G
    Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
    Lichtenstein GR; Onken JE
    Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy.
    Hedenus M; Karlsson T; Ludwig H; Rzychon B; Felder M; Roubert B; Birgegård G
    Med Oncol; 2014 Dec; 31(12):302. PubMed ID: 25373320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre.
    Tan MLN; Windscheif PM; Thornton G; Gaynor E; Rodrigues A; Howarth L
    Eur J Pediatr; 2017 Oct; 176(10):1419-1423. PubMed ID: 28844092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).
    Makharadze T; Boccia R; Krupa A; Blackman N; Henry DH; Gilreath JA
    Am J Hematol; 2021 Dec; 96(12):1639-1646. PubMed ID: 34653287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
    Rognoni C; Ortalda V; Biasi C; Gambaro G
    Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of intravenous ferric carboxymaltose in improving hemoglobin level among postpartum women with moderate-to-severe anemia at a secondary care hospital in Faridabad, Haryana - An interventional study.
    Kant S; Kaur R; Ahamed F; Singh A; Malhotra S; Kumar R
    Indian J Public Health; 2020; 64(2):168-172. PubMed ID: 32584300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.